Drugs / DS-3078a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01588678 | Apr 2012 → Jun 2014 | lymphoma | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-3078a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01588678 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3544963 ↗1“DS-3078a, an Oral TORC1/2 Kinase Inhibitor” NCT01588678 ↗ |
| Route | Oral | “DS-3078a will be administered as oral capsules once daily” NCT01588678 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3544963 ↗ |